INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherapy for Cancer Patients

August 7, 2019 10:07:36
  • INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
  • Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
  • The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field

An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (

“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office